VISTAPH.BO · BSE
VISTA PHARMACEUTICALS LTD.
₹6.58
+5.45% (+₹0.34)
Prev. close
₹6.24
Volume
18,822
As of
24 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About VISTA PHARMACEUTICALS LTD.
Vista Pharmaceuticals Limited manufactures and sells pharmaceutical, medical, and veterinary preparations in India and internationally. It offers over the counter and prescription generic drugs consisting of tablets, capsules, and liquids covering various therapeutic categories. The company was incorporated in 1991 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Dhananjaya Alli
Headquarters
Hyderabad
Website
vistapharmaceuticals.comExchange
View on BSE ↗Key stats
Market cap
₹38.96 Cr
EPS (TTM)
₹-1.90
Beta (1Y · daily vs NIFTY 50)
0.34
Beta (5Y · monthly vs NIFTY 50)
0.50
Shares float
1.39 Cr
EPS · quarter ended Jun 2026
₹-0.16
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1.27 Cr | ₹39.50 L | ₹1.00 Cr | ₹10.29 Cr | ₹10.07 Cr | ₹5.40 Cr | |
| EBITDA | — | — | ₹-3.95 Cr | ₹-3.22 Cr | ₹-3.59 Cr | ₹-14.30 Cr |
| ₹-1.89 Cr | ₹-83.20 L | ₹-5.66 Cr | ₹-4.51 Cr | ₹-4.65 Cr | ₹-12.06 Cr | |
| Diluted EPS | — | — | ₹-1.54 | ₹-1.03 | ₹-0.79 | ₹-1.96 |
Depreciation & amortisation, EBITDA, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹56.02 Cr | ₹57.98 Cr | ₹60.29 Cr | ₹55.08 Cr | |
| — | — | ₹9.96 Cr | ₹7.96 Cr | ₹7.40 Cr | ₹9.99 Cr | |
| Stockholders' equity | — | — | ₹36.71 Cr | ₹40.46 Cr | ₹45.42 Cr | ₹36.44 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹-1.71 Cr | ₹-4.91 Cr | ₹-6.98 Cr | ₹-4.40 Cr | |
| Investing cash flow | — | — | ₹-1.27 Cr | ₹-78.99 L | ₹-44.00 L | ₹-78.21 L |
| — | — | ₹3.11 Cr | ₹5.59 Cr | ₹8.06 Cr | ₹4.56 Cr | |
| Capital expenditure | — | — | ₹-1.27 Cr | ₹-78.99 L | ₹-44.00 L | ₹-78.21 L |
| End cash position | — | — | ₹20.40 L | ₹9.44 L | ₹73.32 L | ₹10.70 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| VISTA PHARMACEUTICALS LTD. | ₹38.96 Cr | ₹6.24 | — | 1.07 | -33.1% | 0.27 | -46.4% | -35.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 27
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
KalVista Pharmaceuticals (KALV) investor SilverArc now reports 0% ownership stake
SilverArc Capital Management, LLC and Devesh Gandhi have reported a 0% ownership stake in KalVista Pharmaceuticals (KALV). The filing indicates they now beneficially own zero shares of the company's Class A Common Stock. This update shows they hold no voting or dispositive power over any shares.
Vista Pharmaceuticals: Q1 2026 Loss Widens to ₹98.59 Lakhs Amidst Financial Strain
Vista Pharmaceuticals reported a net loss of ₹98.59 Lakhs for Q1 2026, marking its sixth consecutive year of financial deficit. The company faces significant financial challenges, including negative working capital and declining net worth, raising doubts about its ability to continue as a going concern. Management is pursuing debt restructuring and cost-saving measures.